New therapeutic approach shows promise for pediatric high-grade gliomas
- OPACC
- Mar 18
- 1 min read
Paediatric high-grade gliomas (pHGG) in particular are a mostly fatal disease group with a median survival time of less than 18 months after diagnosis and limited treatment options. A research team from MedUni Vienna/University Hospital Vienna, the Dana-Farber Cancer Institute and the University of Michigan Medical School identified Platelet-Derived Growth Factor Receptor Alpha (PDGFRA) as a promising therapeutic approach.
Recent Posts
See AllQuality of life improvements can be made if clinicians better understand auditory attention decay after cancer treatment in pediatric...
A team of experts, issuing a statement on behalf of the American Heart Association, have detailed cardiometabolic considerations for...
While the overall prevalence of comorbidities at diagnosis in pediatric patients with acute lymphoblastic leukemia (ALL) and...
Comments